









Markets
/
Stocks
/
nasdaq-tenx
/

Tenax Therapeutics Inc

TENX



View Detailed Chart

13.100USD

+0.280+2.18%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

77.38MMarket Cap

LossP/E TTM



Tenax Therapeutics Inc

13.100

+0.280+2.18%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+2.18%

5 Days

+26.33%

1 Month

+60.74%

6 Months

+126.25%

Year to Date

+111.63%

1 Year

+133.51%

View Detailed Chart

TradingKey Stock Score of Tenax Therapeutics Inc

Currency: USD Updated: 2025-12-19

Key Insights

Tenax Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 17/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 22.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tenax Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

17 / 404

Overall Ranking

88 / 4582

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

22.500

Target Price

+118.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Tenax Therapeutics Inc Highlights

StrengthsRisks

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -17.63, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 4.15M shares, increasing 23.51% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 161.80K shares of this stock.